ArticleVeterinary surgery : VS2026
Safety and feasibility of near-infrared fluorescence imaging with inhaled indocyanine green to assess the pulmonary parenchyma in six normal dogs.
Article in Veterinary surgery : VS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo assess the safety and feasibility of near-infrared fluorescence (NIRF) imaging with inhaled indocyanine green (ICG) to visualize normal pulmonary parenchyma in dogs, report clinically useful information regarding dosage and timing of administration, and to evaluate effects on pulmonary function and tissue histology. STUDY
designPreclinical exploratory study. ANIMALS: Six purpose-bred dogs.
methodsDogs undergoing thoracoscopy were randomly assigned to receive inhaled ICG at 0.1, 0.5, or 1.0 mg/kg. Subjective fluorescence was recorded, images were saved to analyze quantitative fluorescence, and a lung biopsy was obtained. Clinical assessment of respiratory function was performed for 14 days. Peripheral lung biopsies were repeated 6 months later.
resultsInhalation of ICG resulted in real-time NIRF of pulmonary parenchyma in all dogs. Administration time ranged from 1 to 10 min and mean time to first fluorescence was 1.5 min. Peak subjective fluorescence was strong in dogs receiving 0.5 and 1.0 mg/kg, and moderate in dogs receiving 0.1 mg/kg. Peak quantitative fluorescence was positively correlated with dose, with a three-fold and 10-fold increase above baseline 20 min after administration of 0.5 and 1.0 mg/kg doses, respectively. No histologic abnormalities or clinical evidence of respiratory compromise following inhalation of ICG were observed.
conclusionInhaled ICG provided rapid intraoperative fluorescence of normal pulmonary parenchyma, was clinically feasible, and was safe in normal dogs at 0.1-1.0 mg/kg. CLINICAL SIGNIFICANCE: Inhaled ICG produced rapid pulmonary fluorescence without detectable adverse effects, supporting further investigation of its effectiveness to identify pulmonary lesions in dogs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.